Last reviewed · How we verify
NCT03316664: CBTSZ
Assessment of Efficacy of a Psychological Therapy in Inpatients With a Schizophrenic Psychosis
NA trial testing Integrated Neurocognitive Therapy (INT) in Schizophrenia in 82 participants. Completed in 31 August 2021.
31 July 2021
Quick facts
| Lead sponsor | Psychiatric University Hospital, Zurich |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 82 |
| Start date | 1 June 2018 |
| Primary completion | 31 July 2021 |
| Estimated completion | 31 August 2021 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Integrated Neurocognitive Therapy (INT)
- Integrated Psychological Therapy (IPT)
- COGPACK
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
- Schizoaffective Disorder — all drugs for Schizoaffective Disorder →
- Psychotic Disorders — all drugs for Psychotic Disorders →
Sponsor
Psychiatric University Hospital, Zurich
Who can join
Adults 18 to 65, any sex, with Schizophrenia or Schizoaffective Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomised three-arm study aims to evaluate the efficacy and feasibility of a cognitive behavioral therapy (INT-Integrated Neurocognitive Therapy for Schizophrenia Patients) in the treatment of schizophrenia patients in an inpatient setting. The intervention will be compared with an active comparator (IPT- Integrated Psychological Therapy) and a control condition. Overall the study will include 90 patients (30 in each arm). Each patient will receive at least 16 sessions of the respective treatment. Baseline and follow up assessments up to 12 months after the intervention will investigate the stability of treatment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Feasibility and Efficacy of a Psychological Therapy for Patients With a Schizophrenic Psychosis in an Inpatient Setting: Study Protocol of a Randomized Switch Controlled Trial.
Redlich Bossy M, Mueller D, Seifritz E, Vetter S, et al · · 2020 · cited 3× · PMID 32903368 · DOI 10.3389/fpubh.2020.00391
Verify or expand the search:
- PubMed search for NCT03316664
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Other Psychiatric University Hospital, Zurich trials
Trials by the same sponsor.
- NCT04100213 — Real-Time Assessment of Stress and Stress Response · NA · withdrawn
- NCT05939765 — Pharmacologic Treatment in Legal Offenders With Schizophrenia, a Prospective Observational Mirror Image Study. · withdrawn
- NCT04096625 — Enhancement of a Psychotherapeutic Intervention Through Transcranial Direct Current Stimulation (tDCS) · NA · unknown
- NCT05902819 — Reconsolidation Blockade of Intrusive Trauma- and Cocaine-related Memories · NA · completed
- NCT05911529 — Motivational Interviewing for Patients With Acute Psychosis · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03316664 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Psychiatric University Hospital, Zurich
- Last refreshed: 16 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03316664.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing